$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 ...

New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Shares of biotech outfit Cassava Sciences Inc. fell after the publication Science reported Thursday that an investigation accused a neuroscientist who often collaborated with the company of ...

Cassava Sciences (SAVA) announced on Thursday that the Fraud Section of the U.S. Department of Justice has closed an investigation into the company over allegations related to its research misconduct.

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York ...

Good biotech companies develop and commercialize medicines that are safe and effective. Good medicines tend to be the result of good science. And while defining good science is beyond the scope of ...

The controversy about alleged data manipulation related to simufilam was stirred up again by a leaked report. Cassava's response noted that the report from CUNY didn't make any findings of data ...